Skip to main content
. Author manuscript; available in PMC: 2022 May 9.
Published in final edited form as: Neurobiol Dis. 2018 Jun 23;126:47–61. doi: 10.1016/j.nbd.2018.05.011

Figure 1. The CK2 small molecule inhibitor, CX-4945, promotes function recovery in young axons following OGD.

Figure 1.

Pre-treatment with CX-4945 (5 μM) (CK2, red; A and B) applied before OGD promoted a consistent and sustained CAP area recovery. A) Examples of CAP traces taken at baseline (a), OGD (b), and recovery (c) for control and CX-4945 (5 μM). Arrow shows sustained CAP at the end of OGD following CX-4945. B) Time course shows minimal recovery following OGD (black); pre-treatment with CX-4945 (5 μM, red) preserved CAP area during OGD and improved axon function following recovery. C) CX-4945 improved CAP area recovery at 1 and 5 μM, but conferred no protection at 10 μM, when compared to control CAP area recovery. D) CX-4945 had no effect on optic nerve baseline excitability. Scale bar = 1 ms. ** p < 0.01, one-way ANOVA with Newman-Keuls post hoc test.